This ruling substantially increases the probability of a large settlement or adverse judgment against Sandoz and other defendants. Monitor for settlement announcements, trial scheduling, and any disclosures of estimated exposure in subsequent SEC filings. The broad agreement finding expands liability beyond individual drug conspiracies to an overarching scheme.
Price Chart
Executive Summary
The court denied in part and granted in part defendant John Wesolowski's (former Perrigo executive) motion for summary judgment in a multi-state antitrust price-fixing case involving dozens of generic drugs. The ruling allows claims against Wesolowski to proceed on 18 of 28 alleged drug conspiracies, finding sufficient evidence that he participated in or directed collusive communications with competitors. This is an interlocutory ruling — it does not resolve liability or award damages, but it significantly increases the litigation risk and potential settlement exposure for Sandoz (as successor to Fougera) and other named defendants.
Court Ruling Details
Key Facts
- Ruling denies summary judgment to Wesolowski on 18 drug conspiracies, including Adapalene, Bromocriptine, Cal Beta Dip, Clindamycin, Erythromycin, Imiquimod, Tacrolimus, and others
- Court found direct evidence of a 'broad agreement' between Perrigo and Fougera/Sandoz covering all cross-competing drugs from 2010 through September 2015
- Sandoz admitted in a 2020 Deferred Prosecution Agreement to fixing prices on desonide ointment with Perrigo
- Cooperating witnesses (Thomassey, Bihari) provided direct testimony of price-fixing and customer-allocation agreements involving Perrigo and Sandoz
- Claims dismissed for 10 drugs including Econazole (2014), Halobetasol (2012/2013 price increases), and several others where no evidence tied Wesolowski to the conspiracy
- Statute of limitations arguments rejected — continuing violation doctrine applies due to sustained elevated prices
Financial Impact
Not quantified in the ruling; potential exposure includes treble damages on supracompetitive pricing across 18 generic drugs over a multi-year period, plus state penalties and attorneys' fees
Risk Factors
- Potential treble damages and penalties across 18+ generic drug markets
- Settlement pressure increases significantly after this ruling
- Reputational harm and potential follow-on private lawsuits from drug purchasers
- Continuing litigation costs and management distraction
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-7c8267914d-SDZ |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | Court Ruling | — | awaiting T+20 | — | — |
Oct 7, 2026 20d ago | Court Ruling | — | awaiting T+20 | — | — |
Sep 30, 2026 27d ago | Court Ruling | — | awaiting T+20 | — | — |
Sep 30, 2026 27d ago | Court Ruling | — | awaiting T+20 | — | — |
Sep 11, 2026 6w ago | Court Ruling | — | awaiting T+20 | — | — |
Aug 12, 2026 10w ago | Court Ruling | — | awaiting T+20 | — | — |
Aug 6, 2026 11w ago | Court Ruling | — | awaiting T+20 | — | — |
Jul 22, 2026 13w ago | Court Ruling | — | awaiting T+20 | — | — |
Jul 8, 2026 15w ago | Court Ruling | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers